HARBIN, China, Dec. 24 China Sky OneMedical, Inc. (OTC Bulletin Board: CSKI), a manufacturer, marketer anddistributor of pharmaceutical, medicinal and diagnostic products in China,today announced that it has appointed Sherb & Co., LLP as its independentauditor, effective immediately. Mr. Yanqing Liu, Chief Executive Officer andPresident of China Sky One Medical, Inc. stated, "We are pleased to announceour appointment of this globally established accounting firm which has strongexperience in working with public companies. We believe that Sherb & Co. willprovide us with audit services of the highest quality and we look forward toworking with them in the future."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding companywhose principal operations are through its subsidiaries, which are engaged inthe manufacturing, marketing and distribution of pharmaceutical, medicinal anddiagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian DiRen Medical Science and Technology Company ("TDR") and Harbin First Bio-Engineering Company Limited ("First"), the Company's principal revenue sourceis the manufacture and sale of over-the-counter pharmaceutical products.http://www.skyonemedical.com.
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should,""project," "plan," "seek," "intend," or "anticipate" or the negative thereofor comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.CONTACT In the United States: Ashley Ammon MacFarlane and Bill Zima Integrated Corporate Relations, Inc. 203-682-8200 (Investor Relations) In Asia: Xuyang Zhang Integrated Corporate Relations, Inc. 86 10 8523 3087 (Investor Relations)
SOURCE China Sky One Medical, Inc.